G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has predictably returned. There is only one way to respond to such situations, and that is to fire up the coffee kettle and quaff a cup or three of stimulation. Our flavor this morning is Jack Daniels. Yes, you read that correctly. Such a thing exists and we find it quite helpful. While you mull this over, here are some tidbits to help you along. Hope your day is smashing and do keep in touch …

President Trump’s much-ballyhooed drug pricing address contained little of the fiery rhetoric in his campaign speeches and off-script asides, and the policy document that was supposed to detail his vague remarks offered more flash than specifics, STAT writes. It’s unclear how the proposals would work independently or together to actually save money for patients. The blueprint offers few details on how any ideas would be implemented, and barely commits the government to doing anything, often saying the Department of Health and Human Services “may” take certain actions.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy